Regencell Bioscience shares exploded higher during the regular session, outperforming the broader healthcare sector. While the company did not release any specific news, the move occurred against a backdrop of significant activity in the pharmaceutical industry, highlighted by Regeneron Pharmaceuticals reaching a new 52-week high of $849.93 following strong quarterly results. This positive sentiment in the drug manufacturing space appears to have provided a tailwind for the stock, allowing it to climb above its 50-day moving average despite the lack of company-specific catalysts.